Retinal Consultants of Arizona Now Offers CentraSight Treatment Program
Wednesday, January 07, 2015 | Practice Development
Retinal Consultants of Arizona (RCA) has been selected as part of the continuity of care team for patients of the CentraSight Treatment Program. CentraSight is a first-of-kind treatment program that utilizes a tiny telescope implant for end-stage AMD, according to a company news release.
Approximately 500 patients across the country have received the telescope implant to date, and Retinal Consultants of Arizona is one of 100 CentraSight teams in the US. No surgeries have been performed to date in the Phoenix area.
The telescope implant is FDA approved for patients age 65 and older and is the only surgical option that improves visual acuity by reducing the impact of the central vision blind spot caused by end-stage AMD. The cost for the telescope implant and visits associated with the treatment program are Medicare eligible.
Patients with end-stage AMD suffer from a central blind spot. This vision loss makes it difficult or impossible to see faces, read, and perform everyday activities such as watching TV, preparing meals, and performing self-care. The telescope implant has been demonstrated in clinical trials to improve quality of life by improving patients’ vision so they can see the things that are important to them, increase their independence, and re-engage in everyday activities. It also may help patients in social settings as it may allow them to recognize faces and see the facial expressions of family and friends.
Smaller than a pea, the telescope implant uses micro-optical technology to magnify images that would normally be seen in one’s “straight ahead” or central, vision. The images are projected onto the healthy portion of the retina not affected by the disease, making it possible for patients to see or discern the central vision object of interest.
“The CentraSight Treatment Program offers new hope and an improved quality of life for patients suffering with central vision blindness due to late-stage age-related macular degeneration,” Derek Kunimoto, MD, retina ophthalmologist and co-managing partner, Retinal Consultants of Arizona, said in the news release. “We are proud to be the leading referral practice in the Phoenix Valley for this breakthrough treatment plan.”
Arizona patients or caregivers interested in learning more should contact Retinal Consultants of Arizona at 602-222–2221.
You must be logged in to leave a comment.